Search for New Drugs in HIV/AIDS Clinical Care

Physician-authored summaries on the latest research on new drugs, editorials on new drugs, and perspectives on new drugs - drawn from the top medical journals.

Sort by:

Relevance
Date

Items 1 to 20 of 40 results

You searched for: new drugs in HIV/AIDS

New Drugs
- September 1, 2003
- Paul E. Sax, MD
- HIV/AIDS
Several industry-supported studies provide information on new drugs in various stages of development, including the PIs tipranavir, TMC-114, and 908 (the amprenavir prodrug), and the NRTI SPD754.
- Related Searches: aplaviroc, chemokine (c-c motif) receptor 5, darunavir, efavirenz, hiv, lamivudine, lopinavir/ritonavir, maraviroc, reverse transcriptase inhibitors, reverset, ritonavir, tenofovir, vicriviroc, zidovudine
New Drugs
- September 14, 2005
- Judith Feinberg, MD
- HIV/AIDS
CCR5 antagonists created quite a buzz at IAS: Several are entering phase III trials and could be available in the next 2 to 3 years.
- Related Searches: aplaviroc, chemokine (c-c motif) receptor 5, darunavir, efavirenz, hiv, lamivudine, lopinavir/ritonavir, maraviroc, reverse transcriptase inhibitors, reverset, ritonavir, tenofovir, vicriviroc, zidovudine
Antiretroviral Drug Resistance Testing — Updated Guidelines from the IAS–USA
- July 14, 2008
- Charles B. Hicks, MD
- HIV/AIDS
The latest guidelines include updated information on resistance to both old and new drugs and provide specific recommendations for the clinical application of resistance testing.
- Reviewing:
- Hirsch MS et al., Clin Infect Dis 2008 Jul 15; 47:266.
- Related Searches: anti-retroviral agents, drug resistance, viral, guidelines, hiv
Opportunistic Infections: TB, HIV, and XDR TB Free
- March 10, 2008
- Gerald H. Friedland, MD
- HIV/AIDS
Data presented at the 15th Retrovirus Conference highlighted the importance of strengthening airborne infection-control practice and relying less on hospital TB care, particularly in resource-limited settings.
- Related Searches: acquired immunodeficiency syndrome, africa south of the sahara, hiv, multidrug-resistant tuberculosis, tuberculosis, tuberculosis and hiv, tuberculosis, extensively drug-resistant
Clinical Benefit of Continuing a Failing ART Regimen in AIDS Patients Free
- January 14, 2008
- Keith Henry, MD
- HIV/AIDS
In a large study of patients with CD4 counts <200 cells/mm3, the risk for a new AIDS-defining event was 22% lower during periods of virologic failure on ART than during treatment interruptions.
- Reviewing:
- Kousignian I et al., Clin Infect Dis 2008 Jan 15; 46:296.
- Related Searches: acquired immunodeficiency syndrome, anti-retroviral agents, drug holiday, hiv
Top HIV/AIDS Stories of 2007 Free
- December 28, 2007
- Paul E. Sax, MD
- HIV/AIDS
A perspective on the year’s most important stories in HIV medicine
- Related Searches: abacavir, acquired immunodeficiency syndrome, aids vaccines, antiretroviral therapy, highly active, antiviral agents, darunavir, elvitegravir , etravirine, hiv, hiv integrase inhibitors, hiv prevention, hiv screen, lopinavir, male circumcision, maraviroc, multidrug-resistant hiv, raltegravir
Updated Antiretroviral Treatment Guidelines from DHHS and EACS Free
- December 10, 2007
- Carlos del Rio, MD
- HIV/AIDS
The latest guidelines include new recommendations on resistance testing, earlier initiation of therapy, and use of HLA B*5701 testing in patients considering abacavir.
- Related Searches: abacavir, anti-retroviral agents, atazanavir, drug resistance, drug resistance, viral, guidelines, hiv, hla-b5701, lamivudine, maraviroc, multidrug-resistant hiv, ritonavir, tenofovir, zidovudine
Raltegravir, a New HIV Integrase Inhibitor Free
- October 22, 2007
- Rajesh T. Gandhi, MD
- HIV/AIDS
Because raltegravir inhibits a novel viral target, even HIV that is resistant to other antiretroviral-medication classes is sensitive to this drug.
- Related Searches: anti-retroviral agents, hiv, integrase inhibitors, raltegravir
Two Boosted PIs Are Not Better Than One
- August 30, 2007
- Sonia Nagy Chimienti, MD
- HIV/AIDS
In a retrospective analysis, salvage regimens that contained two full-dose PIs plus ritonavir had similar virologic efficacy to those that contained one boosted PI.
- Reviewing:
- Petersen ML et al., AIDS 2007 Jul 31; 21:1547-54.
- Related Searches: anti-retroviral agents, hiv, protease inhibitor, ritonavir, salvage therapy, viral load result
Viral Rebound Rates Decrease over Time in Suppressed Patients
- August 6, 2007
- Keith Henry, MD
- HIV/AIDS
In a U.K.-based cohort study, viral rebound rates fell over time among patients achieving plasma HIV RNA levels ≤50 copies/mL; after 4 years of continuous suppression, rates were similar in patients with and without a history of treatment failure.
- Reviewing:
- Benzie AA et al., AIDS 2007 Jul 11; 21:1423-30.
- Related Searches: hiv, hiv rna rebound, treatment failure, virus replication
New Classes, New Agents: Changing the Paradigm of Antiretroviral Treatment? Free
- April 2, 2007
- Judith Feinberg, MD
- HIV/AIDS
Raltegravir (the first integrase inhibitor) and maraviroc (the first CCR5 inhibitor) are both effective and well tolerated in highly treatment-experienced patients.
- Related Searches: anti-retroviral agents, hiv, integrase inhibitors, maraviroc, raltegravir
Expanded HIV Treatment in Resource-Poor Countries Free
- December 29, 2006
- HIV/AIDS
Initial concerns that antiretroviral therapy would be less effective in resource-poor settings ― or that patients there would be less adherent ― appear to be unfounded.
- Related Searches: anti-retroviral agents, hiv, lamivudine, nevirapine, patient compliance, poverty, stavudine
Promising New Options for Treatment-Experienced Patients Free
- December 29, 2006
- HIV/AIDS
Even triple-class–experienced patients can achieve virologic suppression with some of the new agents now available.
- Related Searches: anti-retroviral agents, darunavir, etravirine, hiv, integrase inhibitors, maraviroc, mk-0518, protease inhibitor, reverse transcriptase inhibitors, salvage therapy
A Role for Foscarnet in HIV?
- October 16, 2006
- Helmut Albrecht, MD
- HIV/AIDS
Results were promising with this pyrophosphate analogue, but the availability of newer drugs in other classes might obviate the need to use foscarnet as salvage therapy.
- Reviewing:
- Canestri A et al., Antivir Ther 2006; 11:561-6.
- Related Searches: cytomegalovirus, cytomegalovirus infection, darunavir, etravirine, foscarnet, hiv, human herpesvirus 8, integrase inhibitors, maraviroc, mk-0518, salvage therapy, stavudine, tenofovir, tipranavir, zidovudine
Mortality Rates in the First Year of Treatment in Low- Versus High-Income Countries
- April 12, 2006
- Keith Henry, MD
- HIV/AIDS
Patients starting potent antiretroviral therapy in low-income countries have similar rates of virologic suppression and immunologic recovery as patients in high-income counties, but they still have higher initial mortality rates.
- Reviewing:
- The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups., Lancet 2006 Mar 11; 367:817-24. , Lancet 2006 Mar 11; 367:789. Ford N and Darder M., Lancet 2006 Mar 11; 367:794-5.
- Related Searches: antiretroviral therapy, highly active, hiv
HIV Drug Resistance in Europe
- September 28, 2005
- Charles B. Hicks, MD
- HIV/AIDS
Two new studies suggest that 10% of treatment-naive patients in Europe — and 20% of treated patients in the U.K. specifically — have resistance to HIV drugs.
- Reviewing:
- Wensing AMJ et al., J Infect Dis 2005 Sep 15; 192:958-66. UK Collaborative Group on HIV Drug Resistance., J Infect Dis 2005 Sep 15; 192:967-73.
- Related Searches: anti-retroviral agents, CATCH, drug resistance, europe, hiv, reverse transcriptase inhibitors, sexually transmitted diseases
FDA Approval: Tipranavir
- June 29, 2005
- HIV/AIDS
Tipranavir (Aptivus), a nonpeptidic PI with activity against many PI-resistant viruses, was given accelerated approval by the FDA on June 22, 2005. The drug must . . .
- Related Searches: hiv, protease inhibitor, tipranavir
Report from the 12th Retrovirus Conference
- March 21, 2005
- HIV/AIDS
This year's Retrovirus Conference returned to Boston, and despite predictably wintry weather, the premier scientific HIV meeting again attracted researchers and clinicians from all over . . .
- Related Searches: acquired immunodeficiency syndrome, aids vaccines, anti-retroviral agents, drug holiday, drug resistance, hepatitis, hepatitis c, hepatitis c virus, hiv, hiv infection syndrome, acute, hiv prevention, hiv transmission, lipodystrophy, patient compliance, poverty, salvage therapy, tuberculosis
Meeting Report from the XV International AIDS Conference
- September 1, 2004
- HIV/AIDS
The XV International AIDS Conference was held in Bangkok, Thailand from July 11 to 14, under the banner "Access for All." The conference was the . . .
Putting Resistance to Work
- July 1, 2004
- HIV/AIDS
A 42-year-old-man was diagnosed with HIV infection in 1992; his CD4 count at the time was 300 cells/mm3. He soon started on a . . .

Sort by:

Relevance
Date

Items 1 to 20 of 40 results

Search

Sign-In

Forgot your password?

Search for New Drugs in HIV/AIDS Clinical Care

New Drugs

New Drugs

Antiretroviral Drug Resistance Testing — Updated Guidelines from the IAS–USA

Opportunistic Infections: TB, HIV, and XDR TB Free

Clinical Benefit of Continuing a Failing ART Regimen in AIDS Patients Free

Top HIV/AIDS Stories of 2007 Free

Updated Antiretroviral Treatment Guidelines from DHHS and EACS Free

Raltegravir, a New HIV Integrase Inhibitor Free

Two Boosted PIs Are Not Better Than One

Viral Rebound Rates Decrease over Time in Suppressed Patients

New Classes, New Agents: Changing the Paradigm of Antiretroviral Treatment? Free

Expanded HIV Treatment in Resource-Poor Countries Free

Promising New Options for Treatment-Experienced Patients Free

A Role for Foscarnet in HIV?

Mortality Rates in the First Year of Treatment in Low- Versus High-Income Countries

HIV Drug Resistance in Europe

FDA Approval: Tipranavir

Report from the 12th Retrovirus Conference

Meeting Report from the XV International AIDS Conference

Putting Resistance to Work

Search

New to Journal Watch?